A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Schizophrenia
Interventions
DRUG

aripiprazole

Tablets, Oral, 5 mg, 10 mg, 15 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional).

DRUG

Placebo

Tablets, Oral, 0 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional)

Trial Locations (57)

Unknown

Local Institution, Graz

Local Institution, Innsbruck

Local Institution, Vienna

Local Institution, Brno - Bohunice

Local Institution, Hradec Králové

Local Institution, Litoměřice

Local Institution, Opava

Local Institution, Prague

Local Institution, Helsingin Kaupunki

Local Institution, Tampere

Local Institution, Turku

Local Institution, Brumath

Local Institution, Bully-les-Mines

Local Institution, Clermont-Ferrand

Local Institution, Limoges

Local Institution, Lyon

Local Institution, Nîmes

Local Institution, Paris

Local Institution, Rennex Cedex 7

Local Institution, Sotteville-lès-Rouen

Local Institution, Augsburg

Local Institution, Berlin

Local Institution, Duisburg

Local Institution, Haar

Local Institution, Heidelberg

Local Institution, Mannheim

Local Institution, Budapest

Local Institution, Szolnok

Local Institution, Krakow

Local Institution, Leszno

Local Institution, Skorzewo

Local Institution, Torun

Local Institution, Warsaw

Local Institution, Soweto

Local Institution, Vereeniging

Local Institution, Durban

Local Institution, Bellville

Local Institution, Cape Town

Local Institution, Bromma

Local Institution, Falköping

Local Institution, Linköping

Local Institution, Luleå

Local Institution, Malmo

Local Institution, Solna

Local Institution, Uppsala

Local Institution, Varberg

Local Institution, Västra Frölunda

Local Institution, Bern

Local Institution, Antalya

Local Institution, Istanbul

Local Institution, Izmir

Local Institution, Exeter

Local Institution, Teignmouth

Local Institution, Welwyn Garden City

Local Institution, Hull

Local Institution, Dundee

Local Institution, London

Sponsors
All Listed Sponsors
collaborator

Otsuka America Pharmaceutical

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY